Ilginatinib (NS018; NS-018) is an orally bioavailable, small molecule inhibitor of Janus-associated kinase 2 (JAK2) and Src-family kinases, with potential antineoplastic activity.

Pacritinib (formerly also known as SB-1518; SB1518; trade name Vonjo) is a novel, potent, selective, and orally bioavailable inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with potential antitumor activity.

WHI-P97 is a novel, rationally designed, and potent inhibitor of Janus kinase (JAK)-3 with an estimated Ki value of 0.09 μM in modeling studies and a measured IC50 value of 2.5 μM in EGFR kinase inhibition assays.

Momelotinib (formerly CYT-387; CYT-11387; LM-1149), an aminopyrimidine analog, is a novel, potent and ATP-competitive inhibitor of Janus kinases (JAK1/2) with potential antitumor and anti-inflammatory activity.

Ruxolitinib Phosphate (Jakafi and Jakavi), the phosphate salt of ruxolitinib which is also known as INC424, INCB18424 or INCB018424, is a first-in class, potent, selective, and orally bioavailable JAK1/2 (Janus-associated kinase) inhibitor with IC50 of 3.3 nM/2.8 nM in cell-free assays, it exhibits >130-fold selectivity for JAK1/2 versus JAK3.

GLPG0634 analogue, an analog of Filgotinib (GLPG0634), is a novel, potent and selective Janus kinase-JAK1 inhibitor with potential anti-inflammatory activity.

Ruxolitinib (formerly INC424, INCB18424, INCB018424; trade name Jakafi and Jakavi) is the first-in class, potent, selective, and orally bioavailabe JAK1/2 (Janus-associated kinase) inhibitor with IC50 of 3.3 nM/2.8 nM in cell-free assays, it exhibits >130-fold selectivity for JAK1/2 versus JAK3.

Golidocitinib (AZD-4205; JAK1-IN-3) is a novel and potent JAK1 (Janus Kinase) inhibitor with anticancer activity.

Baricitinib, (also known as LY3009104 or INCB028050; trade name: Olumiant), is a potent, selective, ATP competitive and orally bioavailable inhibitor of tyrosine-protein kinase JAK1 (Janus kinase) or JAK2 with anti-inflammatory activity.